HK1160724A1 - A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro- 1h-pyridin-2-one and one or more additional antiviral compounds - Google Patents

A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro- 1h-pyridin-2-one and one or more additional antiviral compounds

Info

Publication number
HK1160724A1
HK1160724A1 HK12100657.0A HK12100657A HK1160724A1 HK 1160724 A1 HK1160724 A1 HK 1160724A1 HK 12100657 A HK12100657 A HK 12100657A HK 1160724 A1 HK1160724 A1 HK 1160724A1
Authority
HK
Hong Kong
Prior art keywords
pyridin
dihydro
virus
combination
antiviral compounds
Prior art date
Application number
HK12100657.0A
Other languages
English (en)
Inventor
Peter S Dragovich
Peggy A Thompson
Frank Ruebsam
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of HK1160724A1 publication Critical patent/HK1160724A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
HK12100657.0A 2008-10-09 2012-01-20 A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro- 1h-pyridin-2-one and one or more additional antiviral compounds HK1160724A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10415208P 2008-10-09 2008-10-09
PCT/US2009/060189 WO2010042834A1 (en) 2008-10-09 2009-10-09 A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds

Publications (1)

Publication Number Publication Date
HK1160724A1 true HK1160724A1 (en) 2012-08-17

Family

ID=42100979

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12100657.0A HK1160724A1 (en) 2008-10-09 2012-01-20 A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro- 1h-pyridin-2-one and one or more additional antiviral compounds

Country Status (6)

Country Link
US (2) US20110229438A1 (zh)
EP (1) EP2346329B1 (zh)
ES (1) ES2435799T3 (zh)
HK (1) HK1160724A1 (zh)
TW (1) TWI480272B (zh)
WO (1) WO2010042834A1 (zh)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
CN102325783A (zh) 2008-12-23 2012-01-18 法莫赛特股份有限公司 嘌呤核苷的合成
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
JP5795316B2 (ja) 2009-09-04 2015-10-14 ヤンセン ファーマシューティカルズ，インコーポレーテッド 化合物
BR112012010110A2 (pt) 2009-10-30 2019-09-24 Boehringer Ingelheim Int regimes de dosagem para terapia combinada para hcv compreendendo bi201335, interferon alfa e ribavirina
US20130029904A1 (en) 2009-12-18 2013-01-31 Boehringer Ingelheim International Gmbh Hcv combination therapy
MY156888A (en) * 2010-03-10 2016-04-15 Abbvie Bahamas Ltd Solid Compositions
SG184323A1 (en) 2010-03-31 2012-11-29 Gilead Pharmasett Llc Stereoselective synthesis of phosphorus containing actives
US8563530B2 (en) 2010-03-31 2013-10-22 Gilead Pharmassel LLC Purine nucleoside phosphoramidate
US20120196794A1 (en) * 2010-08-06 2012-08-02 Bristol-Myers Squibb Company Combinations of Hepatitis C Virus Inhibitors
CN106117068A (zh) * 2010-09-29 2016-11-16 宝洁公司 合成2‑取代的‑1,4‑二苯胺的方法
CA2818853A1 (en) 2010-11-30 2012-06-07 Gilead Pharmasset Llc 2'-spirocyclo-nucleosides for use in therapy of hcv or dengue virus
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
JP2014506255A (ja) 2010-12-30 2014-03-13 エナンタ ファーマシューティカルズ インコーポレイテッド フェナントリジン大環状ｃ型肝炎セリンプロテアーゼ阻害剤
US20120321590A1 (en) * 2011-04-06 2012-12-20 Anadys Pharmaceuticals, Inc. Bridged polycyclic compounds
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
EP2747569A4 (en) * 2011-08-24 2015-07-08 Glaxosmithkline Llc COMBINATION TREATMENTS FOR HEPATITIS C
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US20130302414A1 (en) * 2012-05-07 2013-11-14 Bristol-Myers Squibb Company Solubilized capsule formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate
BR112014030623A2 (pt) * 2012-06-12 2017-06-27 Hoffmann La Roche composição, combinação e respectivos usos
EP2943468B1 (en) * 2013-01-14 2017-03-01 F. Hoffmann-La Roche AG A novel process for the preparation of n-(4-nitro-2-sulfamoyl-phenyl)-malonamic acid methyl ester and n-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester
PL3038601T3 (pl) 2013-08-27 2020-08-24 Gilead Pharmasset Llc Formulacja złożona dwóch związków przeciwwirusowych
EP3089757A1 (en) 2014-01-03 2016-11-09 AbbVie Inc. Solid antiviral dosage forms
US9822030B2 (en) * 2015-02-13 2017-11-21 Corning Incorporated Ultralow expansion titania-silica glass

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ZA791659B (en) 1978-04-17 1980-04-30 Ici Ltd Process and apparatus for spraying liquid
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
GB8504253D0 (en) 1985-02-19 1985-03-20 Ici Plc Electrostatic spraying apparatus
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
GB9225098D0 (en) 1992-12-01 1993-01-20 Coffee Ronald A Charged droplet spray mixer
GB9226717D0 (en) 1992-12-22 1993-02-17 Coffee Ronald A Induction-operated electro-hydrodynamic spray device with means of modifying droplet trajectories
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
GB9406171D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9406255D0 (en) 1994-03-29 1994-05-18 Electrosols Ltd Dispensing device
GB9410658D0 (en) 1994-05-27 1994-07-13 Electrosols Ltd Dispensing device
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1996028205A1 (en) 1995-03-14 1996-09-19 Siemens Aktiengesellschaft Ultrasonic atomizer device with removable precision dosing unit
JP3585127B2 (ja) 1995-03-14 2004-11-04 シーメンス アクチエンゲゼルシヤフト 超音波噴霧システム
SE506529C2 (sv) 1996-01-23 1997-12-22 Semper Ab Användning av ett laktoperoxidassystem för framställning av ett läkemedel mot Helicobacter pylori
NZ504021A (en) 1997-10-17 2003-04-29 Systemic Pulmonary Delivery Lt Method and apparatus for delivering aerosolized medication having air discharged through air tube directly into plume of aerosolized medication
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
KR20030017569A (ko) * 2000-06-28 2003-03-03 테바 파마슈티컬 인더스트리즈 리미티드 카르베딜올
AR036081A1 (es) 2001-06-07 2004-08-11 Smithkline Beecham Corp Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos
AU2002365198A1 (en) 2001-10-30 2003-07-30 Smithkline Beecham Corporation Novel anti-infectives
US20050075331A1 (en) * 2003-10-06 2005-04-07 Pratt John K. Anti-infective agents
US7601709B2 (en) * 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
US7378414B2 (en) * 2003-08-25 2008-05-27 Abbott Laboratories Anti-infective agents
US7439246B2 (en) * 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
ATE437875T1 (de) * 2004-08-23 2009-08-15 Hoffmann La Roche Heterozyklische antivirale verbindungen
AU2005316396A1 (en) * 2004-12-17 2006-06-22 Anadys Pharmaceuticals, Inc. Pyridazinone compounds
AU2006243245A1 (en) 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CN101501039B (zh) 2006-06-22 2012-02-22 安那迪斯药品股份有限公司 吡咯并[1,2-b]哒嗪酮化合物
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CL2007003587A1 (es) * 2006-12-12 2008-07-04 Anadys Pharmaceuticals Inc Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
US20080214529A1 (en) * 2006-12-12 2008-09-04 Frank Ruebsam SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS
UA100120C2 (en) 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
US20080292588A1 (en) * 2007-05-17 2008-11-27 Anadys Pharmaceuticals, Inc. 1-methyl-benzo[1,2,4]thiadiazine 1-oxide derivatives
CN101796040A (zh) * 2007-07-06 2010-08-04 吉里德科学公司 治疗剂的药代动力学特性调节剂
KR20100056479A (ko) * 2007-07-25 2010-05-27 바이오렉스 쎄라퓨틱스, 인코포레이티드 제어 방출 인터페론 약물 제품 및 이를 사용한 ｈｃｖ 감염의 치료
US7834009B2 (en) * 2007-08-27 2010-11-16 Anadys Pharmaceuticals, Inc. 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds

Also Published As

Publication number Publication date
US20110229438A1 (en) 2011-09-22
EP2346329B1 (en) 2013-08-21
EP2346329A1 (en) 2011-07-27
US20140066396A1 (en) 2014-03-06
WO2010042834A1 (en) 2010-04-15
TW201026676A (en) 2010-07-16
EP2346329A4 (en) 2012-03-28
ES2435799T3 (es) 2013-12-23
TWI480272B (zh) 2015-04-11

Similar Documents

Publication Publication Date Title
HK1160724A1 (en) A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro- 1h-pyridin-2-one and one or more additional antiviral compounds
HRP20160410T8 (hr) Inhibitori hepatitis c virusa
HK1146693A1 (zh) 含喹喔啉的化合物作為丙型肝炎病毒的抑制劑
HK1143812A1 (en) Hepatitis c virus inhibitors
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
AP2907A (en) Viral hepatitis treatment
EP2268619A4 (en) FLUORINATED MACROCYCLIC COMPOUNDS AS INHIBITORS OF HEPATITIS C VIRUS
ZA201001379B (en) Hepatitis c antiviral compositions and methods
IL204547A (en) Oracil derivative for the treatment of hepatitis c
SI2193131T1 (sl) Imidazo(1,2-A)pirazin spojine za zdravljenje virusnih okuĹľb kot je hepatitis
ZA200906129B (en) Compounds for the treatment of hepatitis c
EP2344487A4 (en) HEPATITIS C INHIBITOR COMPOUNDS
PL2209784T3 (pl) Związki do leczenia zapalenia wątroby typu C
WO2010052559A8 (en) Cycloundecadepsipeptide compounds and use of said compounds as a medicament
EP2120988A4 (en) TREATMENT OF HEPATITIS C VIRUS INFECTIONS
EP2351585A4 (en) ANTIVIRUS COMPOSITION OF HEPATITIS C
IL213593A0 (en) Hepatitis c virus combination therapy
EP1726646A4 (en) METHOD FOR DETECTING THERCHEVATITIS B VIRUS CREATED CARCINOGENESIS
ZA200903379B (en) Hepatitis C virus inhibitors
PL381955A1 (pl) Pochodne urydyny jako związki przeciwwirusowe, zwłaszcza przeciwko wirusom z rodziny Flaviviridae
HUS1500008I1 (hu) Hepatitis C vírus inhibitorok
SI2203430T1 (sl) N-fenil-diokso-hidropirimidini, uporabni kot inhibitorji virusa hepatitisa C (HCV)
ZA200903014B (en) Hepatitis C virus inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20181009